Based on ideas of the founders, the team has identified a novel specific immunotherapy approach based on antigen-specific tolerance induction.

The approach defines a platform technology which is broadly applicable to a range of clinical indications with significant unmet medical need.

Allero’s proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with targeted delivery of specific antigens to the oral mucosa, an immune-priviliged target. The goal is to restore normal immune balance, avoiding global immune suppression, and treating the cause of the disease.

Specific Antigens

Tolerance Inducing Agent

Muco-adhesive Delivery Technology


Platfom that can be used for multiple allergy and auto-immune indications.

Enhances tolerance induction by stimulation of proper immune cells.

Optimal retention of therapeutics at common tolerance induction site: the oral mucosa.

Non-invasive and patient-friendly treatment.

Short-course treatment that reinstates tolerance with a long-lasting effect.

Safety key technology components validated in humans.